PM Group

Genzyme Flanders bvba, a subsidiary of the US biotechnology company Genzyme, has a facility in Geel which produces a treatment for B-cell lymphocytic leukemia and a rare and often fatal muscle disorder, Pompe disease.

We designed and delivered this expansion with our alliance partners CRB Consulting Engineers and Grontmij Industry (formerly BnS).

We developed a concept for conversion of the single-product facility, with minimal production interruption, into a facility that will produce two products concurrently.

The scope included adding additional bioreactor capacity (two 4,000L Perfusion bioreactors), a new cold purification train, additional buffer preparation facilities and CIP skids. It also involved modification of the existing cell culture (two 10,000 litre fed batch bio-reactors) and purification train to facilitate production of an alternative product.

The majority of the changes were required in the purification suites and required reconfiguration of the existing train to fit the required process flow and add additional unit operations.

Services provided included:

• Project Management
• Conceptual Design
• Preliminary Engineering
• Permitting
• Detailed Design
• Procurement
• Construction Management
• Commissioning

The PM / Grontmij team is now engaged in the design of a further significant production expansion at the facility.